GW Pharmaceuticals PLC: directors' dealings · United States · SEC (Form 4)

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc was a specialty biopharmaceutical company focused on discovering, developing, and commercializing cannabinoid-based prescription medicines. Founded in 1998 in the United Kingdom, the company built its reputation on a disciplined, science-led approach to cannabinoid therapeutics, targeting areas of high unmet medical need, especially in neurology and rare diseases. For investors, one important point is that GW Pharmaceuticals plc was acquired by Jazz Pharmaceuticals in May 2021. As a result, GWPH is no longer an independent listed company; references to the ticker today are mainly historical and relate to legacy SEC filings, including insider-transaction documentation. In terms of business lines, GW’s core franchise centered on a proprietary cannabinoid platform. Its flagship product was Epidiolex, an oral cannabidiol-based medicine developed for severe treatment-resistant epilepsies, including Dravet syndrome and Lennox-Gastaut syndrome, with additional label expansion over time. The company also commercialized Sativex, a cannabinoid-based therapy used in certain neurological and spasticity-related indications in multiple markets outside the United States. This made GW a pioneer in pharmaceutical-grade cannabinoid medicine, with its competitive positioning derived from clinical evidence, regulatory exclusivity, and drug-development execution rather than from consumer wellness exposure. Historically, GW Pharmaceuticals was incorporated in England and Wales and operated with an international footprint spanning Europe and the United States. Its legacy communications placed the company in the London/Cambridge ecosystem in the United Kingdom, while its U.S. commercial presence became increasingly important as Epidiolex gained traction. On the public markets, GWPH was listed on the Nasdaq in the United States, making it a closely followed name among biotechnology and specialty-pharma investors before its delisting following the acquisition. Recent milestones are dominated by the Jazz Pharmaceuticals transaction. Announced in February 2021 and completed in May 2021, the deal validated the commercial and strategic value of Epidiolex and transferred GW’s assets into a larger global pharmaceutical platform. From an equity-analysis perspective, GW Pharmaceuticals should therefore be viewed as a historically important cannabinoid-pioneer and value-creation story, rather than an operating standalone company currently trading on a U.S. exchange.